By using this site, you agree to the Privacy Policy and Terms of Use.
Accept

Parami News

  • Home
  • Politics
  • India
  • World
  • Business
  • Entertainment
  • Regional
  • Sports
  • Web Stories
Search
© 2024 Parami News. All Rights Reserved.
Reading: Moderna (mRNA) Q1 2024 Earnings | Parami News
Share
Sign In
Notification Show More
Font ResizerAa

Parami News

Font ResizerAa
Search
  • Home
  • Politics
  • India
  • World
  • Business
  • Entertainment
  • Regional
  • Sports
  • Web Stories
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Parami News > Blog > Business > Moderna (mRNA) Q1 2024 Earnings | Parami News
Business

Moderna (mRNA) Q1 2024 Earnings | Parami News

Atulya Shivam Pandey
Last updated: May 2, 2024 8:23 pm
Atulya Shivam Pandey
Share
5 Min Read
Moderna (mRNA) Q1 2024 Earnings

 | Parami News
SHARE

Nikos Pechiaridis | Noor Photos | Getty Images

modern First-quarter losses reported on Thursday were narrower than expected as the company carried out its cost-cutting efforts and sold its Severe special infectious pneumonia vaccineIts only commercial product exceeded expectations.

As Moderna gets closer to putting, the results are in another product urgently needed in the market Require Global COVID-19 vaccinations have plummeted.The biotech company expects its vaccine to win U.S. approval respiratory fusion virus May 12th.

Moderna shares closed up more than 12% on Thursday after the results were announced.

Moderna’s first-quarter report compared with Wall Street expectations, according to a survey of analysts by London Stock Exchange Group (LSEG):

  • Loss per share: $3.07, expected loss of $3.58
  • income: $167 million vs. $97.5 million expected

“We’ve made tremendous progress on the company (operating expense) side,” Moderna Chief Executive Stéphane Bancel said Thursday of the cost cuts on CNBC.scream boxHe added that the biotech company’s team “has done an outstanding job right-sizing the company.”

Moderna’s first-quarter sales were $167 million, with Covid vaccine revenue down about 90% from the same period last year. The company reported revenue of $1.86 billion in the same period last year.

Moderna Chief Financial Officer Jamey Mock said in an interview with CNBC that about $100 million came from the United States and $67 million from international markets, mainly Latin America.

The company said the revenue decline was due in part to an expected transition to a seasonal COVID-19 vaccine market, with patients typically getting vaccinated in the fall and winter.

Moderna reported a first-quarter net loss of $1.18 billion, or $3.07 per share. This compares with net income of $79 million, or 19 cents per share, in the same period last year.

The company reiterated its full-year 2024 sales guidance of about $4 billion, which includes revenue from its RSV vaccine. Notably, Moderna expects sales of just $300 million in the first half of this year, as respiratory virus season typically occurs in the second half.

Executives said on an earnings call Wednesday that the second quarter will include part of the company’s recently announced contract with Brazil to supply 12.5 million coronavirus vaccine doses.

Moderna said it expects to resume sales growth in 2025 and achieve breakeven in 2026 as new products are launched.

For the first quarter, Mock said the company was “more encouraged by what we saw from a productivity perspective” than increased COVID-19 vaccine sales.

Cost of sales in the first quarter was US$96 million, down 88% from the same period last year. This includes a $30 million write-down on unused COVID-19 vaccine doses and a $27 million charge related to the company’s production scale-down.

Research and development expenses fell 6% to $1.1 billion in the first quarter compared with the same period in 2023. Spending on trials is reduced.

Meanwhile, selling, general and administrative expenses for the period fell 10% to $274 million compared with the first quarter of 2023.

The company said part of the decrease was due to its investments in “digital business capabilities” and a greater focus on using artificial intelligence technology to streamline operations.

More CNBC health coverage

Last month, Modena declare Partnering with artificial intelligence heavyweight OpenAI, it aims to automate nearly all business processes for biotech companies.

Mock told CNBC that Moderna has been working with OpenAI for the past year. He added that 60% to 70% of the company’s employees currently use artificial intelligence chatbots to work.

So far, Moderna has managed to boost investor confidence in its path forward post-COVID. The company’s shares are up more than 10% this year on growing confidence in its pipeline and messenger RNA platform, the technology used in its Covid vaccine.

The biotech company currently has 45 products in development, including some in late-stage trials. These include a combination vaccine against COVID-19 and influenza, which could be approved as soon as 2025.

Moderna is also working with Merck & Co. to develop a standalone flu vaccine, a personalized cancer vaccine Injection of latent virusand other products.

Correction: Moderna’s cost of sales for the first quarter was $96 million. An earlier version incorrectly described the time period.

Don’t miss these exclusive reports from CNBC PRO

You Might Also Like

NHL executive and other Latino executives discover Latinos on sports platforms | Parami News

Consumption isn’t slowing down at Sweetgreen, Chipotle and Wingstop | Parami News

Goldman Sachs and American Express are parent-led companies | Parami News

Ford names former Lucid Motors executive as next financial officer and promotes current CEO | Parami News

McDonald’s is developing a $5 value meal | Parami News

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Sanjay Leela Bhansali shares his father’s last wish was to hear Reshma’s ‘Hayo Rabba’: ‘I had no place to play it…’ | Hindi Film News

 | Parami News Sanjay Leela Bhansali shares his father’s last wish was to hear Reshma’s ‘Hayo Rabba’: ‘I had no place to play it…’ | Hindi Film News | Parami News
Next Article At Arti Singh’s wedding, Kashmera Shah introduced her twin sons Krishaang and Rayaan to Govinda’s son Yashvardhan Ahuja; they greeted him with “Namaste”

 | Parami News At Arti Singh’s wedding, Kashmera Shah introduced her twin sons Krishaang and Rayaan to Govinda’s son Yashvardhan Ahuja; they greeted him with “Namaste” | Parami News
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected

235.3kFollowersLike
69.1kFollowersFollow
11.6kFollowersPin
56.4kFollowersFollow
136kSubscribersSubscribe
4.4kFollowersFollow

Latest News

Harry Meghan LA Fire Victims: Major outrage over Harry-Meghan’s visit to LA fire victims: ‘You are not royals…merely two nitwit celebrities’
Harry Meghan LA Fire Victims: Major outrage over Harry-Meghan’s visit to LA fire victims: ‘You are not royals…merely two nitwit celebrities’
World January 11, 2025
‘My chapter is over’: Bangladesh veteran Tamim Iqbal retires from international cricket | Cricket News
‘My chapter is over’: Bangladesh veteran Tamim Iqbal retires from international cricket | Cricket News
Sports January 11, 2025
Graduation ceremony held for university colleges of engineering students
Graduation ceremony held for university colleges of engineering students
India January 11, 2025
Pakistan anti-terrorism court grants bail to more than 150 workers of Imran Khan’s party

 | Parami News
Pakistan anti-terrorism court grants bail to more than 150 workers of Imran Khan’s party | Parami News
Most Recent Stories January 11, 2025
//

We influence 20 million users and is the number one business and technology news network on the planet

Quick Link

  • About Us
  • Contact Us
  • Advertise With Us
  • DNPA Code of Ethics
  • Disclaimer
  • Privacy Policy

Top Categories

  • Business
  • Entertainment
  • India
  • Politics
  • Regional
  • Sports

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Follow US
© 2024 Parami News. All Rights Reserved.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
Welcome Back!

Sign in to your account

Lost your password?